ArticleAnnals of surgical oncology2025
Long-term Outcomes for Neoadjuvant Versus Adjuvant Chemotherapy in ER+/HER2- Locally Advanced Breast Cancer.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of prognostic nutritional index in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Beyond pCR Prediction: Subtype-Specific Artificial Intelligence for Treatment Tailoring in Breast Cancer Neoadjuvant Therapy.Cancers · 2026Review
- Factors Influencing Pathological Complete Response After Neoadjuvant Chemotherapy in Breast Cancer: A Single-Center Retrospective Study Focusing on ER and HER-2 Status.International journal of breast cancer · 2026Article
- Development of a nomogram for predicting axillary pathologic complete response after neoadjuvant therapy in clinically node-positive breast cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe effectiveness of neoadjuvant chemotherapy (NaCT) over adjuvant chemotherapy (ACT) in enhancing long-term survival for ER+/HER2- breast cancer patients is uncertain. This study compares breast cancer-specific survival (BCSS) between these treatments in patients with stage IIB-IIIC ER+/HER2- breast cancer using the SEER database.
methodsData from 46,837 patients who underwent chemotherapy and surgery from 2010-2019 were analyzed. Breast cancer-specific survival was assessed by using multivariable Cox regression, inverse probability of treatment weighting (IPTW), and propensity score-matching (PSM) models, along with subgroup analyses.
resultsOf the study cohort, 78.4% received ACT, and 21.6% received NaCT. Neoadjuvant chemotherapy usage increased from 15.6% in 2010 to 31.4% in 2019. Multivariable analysis indicated a lower BCSS in the NaCT group (hazard ratio [HR] 1.39, 95% confidence interval [CI] 1.31-1.48, P < 0.001), a trend consistent in IPTW and PSM analyses. However, in specific subgroups, particularly younger patients (<40 years) achieving pathologic complete response (pCR), the NaCT group exhibited better BCSS.
conclusionsOverall, NaCT was associated with poorer survival compared to ACT in ER+/HER2- breast cancer. Nonetheless, certain subgroups, especially younger patients achieving pCR, showed potential benefits from NaCT. Future research should aim to identify markers for optimally applying NaCT in ER+/HER2- breast cancer treatment.
Indexed as
Identifiers
40263225What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.